recombinant human il-21-expressing oncolytic vaccinia virus injection
Biologicalexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 29, 2025 (NCT07006077)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Oncolytic virusSupplementation
Oncolytic virus supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07185243 | N/A | Jun 23, 2025 | Hangzhou Converd Co., Ltd., Xiamen Humanity Hospital |
| NCT07006077 | Phase 2 | May 29, 2025 | Hangzhou Converd Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hangzhou Converd Co., Ltd. | For profit | 2 | 2 | 2 | 2025 |
| Xiamen Humanity Hospital | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1